These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11364851)

  • 1. Seldane warnings.
    Vazquez E; Whitfield L
    Posit Aware; 1997; 8(6):12. PubMed ID: 11364851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seldane approval may be withdrawn by FDA.
    AIDS Patient Care STDS; 1997 Jun; 11(3):197-8. PubMed ID: 11361802
    [No Abstract]   [Full Text] [Related]  

  • 3. Is my antihistamine safe?
    Ashworth L
    Home Care Provid; 1997 Jun; 2(3):117-20. PubMed ID: 9274181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New formulation of saquinavir (Fortovase) is more effective.
    Tam CW
    Fac Notes (New Orleans La); 1998; 10(2):11. PubMed ID: 11365126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease inhibitors at a glance...
    Notes Undergr; 1998-1999 Winter; (No 38):suppl 1-4. PubMed ID: 11366198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)-induced ventricular arrhythmias.
    Wynn RL
    Gen Dent; 1993; 41(1):27-9. PubMed ID: 7489857
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA announces plan to halt marketing of terfenadine.
    Am J Health Syst Pharm; 1997 Feb; 54(4):342. PubMed ID: 9043551
    [No Abstract]   [Full Text] [Related]  

  • 8. Protease inhibitors: FDA warns doctors of diabetes risk. Food and Drug Administration.
    AIDS Treat News; 1997 Jun; (No 273):5-6. PubMed ID: 11364400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What they say about protease inhibitors.
    Posit Aware; 1999; 10(1):38-43. PubMed ID: 11366522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Norvir soft-gel capsule formulation approved by FDA.
    Gaylord G
    Posit Living; 1999 Aug; 8(7):11. PubMed ID: 12492076
    [No Abstract]   [Full Text] [Related]  

  • 11. Improved but not new.
    Vazquez E
    Posit Aware; 1997; 8(6):19. PubMed ID: 11364855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goodbye, Invirase. Hello, Fortovase.
    Vazquez E
    Posit Aware; 1998; 9(1):45-6. PubMed ID: 11365001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terfenadine therapy: can we justify the risks?
    Rangno R
    CMAJ; 1997 Jul; 157(1):37-8. PubMed ID: 9220940
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug interactions: Who warns the patient.
    CMAJ; 1999 Jul; 161(2):117. PubMed ID: 10454842
    [No Abstract]   [Full Text] [Related]  

  • 15. An evaluation of drug cocktail combinations for their immunological value in preventing/remitting opportunistic infections.
    Konlee M
    Posit Health News; 1998; (No 16):2-4. PubMed ID: 11365016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA notifications. UCB Pharma and FDA issue advisory letter.
    AIDS Alert; 2004 Feb; 19(2):22-4. PubMed ID: 15011629
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug interactions associated with terfenadine and related nonsedating antihistamines.
    Zechnich AD; Haxby DG
    West J Med; 1996 Jan; 164(1):68-9. PubMed ID: 8779212
    [No Abstract]   [Full Text] [Related]  

  • 18. Party at your own risk.
    Cox S
    Posit Aware; 1997; 8(3):32-7. PubMed ID: 11364423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The younger generation.
    Jefferys R; Forataro K
    Body Posit; 1999 Aug; 12(8):15-6. PubMed ID: 11367065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnant pause.
    Heidere C
    STEP Perspect; 1998; 98(2):5-6. PubMed ID: 11365543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.